RAGE-Aβ interactions in the pathophysiology of Alzheimer's disease

被引:0
|
作者
Yan, SD
Stern, D
Kane, MD
Kuo, YM
Lampert, HC
Roher, AE
机构
[1] Sun Hlth Res Inst, Haldeman Lab Alzheimers Dis Res, Sun City, AZ 85351 USA
[2] Parke Davis, Ann Arbor, MI 48105 USA
[3] Columbia Univ Coll Phys & Surg, Dept Pathol Surg Med & Physiol, New York, NY 10032 USA
关键词
D O I
暂无
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
RAGE is a cell surface molecule primarily identified for its capacity to bind advanced glycation end-products and amphoterin. Immunocytochemical studies demonstrated that in Alzheimer's disease (AD) the expression of RAGE is elevated in neurons close to neuritic plaque beta-amyloid (A beta) deposits and in the cells of A beta containing vessels. Gross-linking of surface bound A beta 1-40 to endothelial cells, yielded a band of 50 kDa identified as RAGE. Using the soluble extracellular domain of recombinant human RAGE, we found that A beta binds to RAGE with a Kd = 57 +/- 14 nM, a value close to those found for mouse brain endothelial cells and rat cortical neurons. The interaction of A beta with RAGE in neuronal, endothelial, and RAGE-transfected COS-1 cells induced oxidative stress, as assessed by the TEARS and MTT assays. ELISA demonstrated a 2.5 times increase of RAGE in AD over control brains. Activated microglia also showed elevated expression of RAGE. In the BV-2 microglial. cell line, RAGE bound A beta in a dose dependent manner with a Kd of 25 +/- 9 nM. Soluble A beta induced the migration of microglia along a concentration gradient, while immobilized A beta arrested this migration. A beta-RAGE interaction also activated NF-kappa B, resulting in neuronal up-regulation of macrophage-colony stimulating factor (M-CSF) which also induced microglial migration. Taken together, our data suggest that RAGE-A beta interactions play an important role in the pathophysiology of Alzheimer's disease.
引用
收藏
页码:167 / 173
页数:7
相关论文
共 50 条
  • [41] Hippocampal RAGE immunoreactivity in early and advanced Alzheimer's disease
    Miller, Miles C.
    Tavares, Rosemarie
    Johanson, Conrad E.
    Hovanesian, Virginia
    Donahue, John E.
    Gonzalez, Liliana
    Silverberg, Gerald D.
    Stopa, Edward G.
    BRAIN RESEARCH, 2008, 1230 : 273 - 280
  • [42] Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease
    Srikanth, Velandai
    Maczurek, Annette
    Thanh Phan
    Steele, Megan
    Westcott, Bernadette
    Juskiw, Damian
    Muench, Gerald
    NEUROBIOLOGY OF AGING, 2011, 32 (05) : 763 - 777
  • [43] Synaptic degeneration and neurogranin in the pathophysiology of Alzheimer's disease
    Lista, Simone
    Hampel, Harald
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (01) : 47 - 57
  • [44] Genetics, pathophysiology and future treatment of Alzheimer's disease
    Lannfelt, L
    NEUROBIOLOGY OF AGING, 2002, 23 (01) : S10 - S11
  • [45] The cell division cycle and the pathophysiology of Alzheimer's disease
    Nagy, Z
    Esiri, MM
    Smith, AD
    NEUROSCIENCE, 1998, 87 (04) : 731 - 739
  • [46] Pathophysiology of neuronal energy crisis in Alzheimer's disease
    de la Torre, Jack C.
    NEURODEGENERATIVE DISEASES, 2008, 5 (3-4) : 126 - 132
  • [47] Pathophysiology of Hypoperfusion of the Precuneus in Early Alzheimer's Disease
    Miners, J. Scott
    Palmer, Jennifer C.
    Love, Seth
    BRAIN PATHOLOGY, 2016, 26 (04) : 533 - 541
  • [48] PATHOPHYSIOLOGY OF ALZHEIMER'S DISEASE: EXPERIMENTAL AND GENETIC FINDINGS
    Saka, Esen
    TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2010, 13 : 21 - 26
  • [49] What is it behind the Alzheimer's disease? A pathophysiology review
    Avila-Funes, JA
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2004, 56 (03): : 375 - 381
  • [50] ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
    Ana-Caroline Raulin
    Sydney V. Doss
    Zachary A. Trottier
    Tadafumi C. Ikezu
    Guojun Bu
    Chia-Chen Liu
    Molecular Neurodegeneration, 17